Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is ArcticZymes Technologies ASA EV-to-EBITDA?
ArcticZymes Technologies ASALTS:0DRV +3.45%74 EV-to-EBITDA is 39.76 as of Aug. 20, 2026, which is 26% below its 10-year median of 53.57. GuruFocus rates LTS:0DRV with a GF Score™ of 74/100 and a GF Value™ of kr25.93 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 402 Biotechnology companies, ArcticZymes Technologies ASA ranks worse than 77.11% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ArcticZymes Technologies ASA's enterprise value is kr827.1 Mil.
ArcticZymes Technologies ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr20.8 Mil. Therefore, ArcticZymes Technologies ASA's EV-to-EBITDA for today is 39.76.
The historical rank and industry rank for ArcticZymes Technologies ASA's EV-to-EBITDA or its related term are showing as below:
LTS:0DRV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -738.44 Med: 53.57 Max: 3189.91
Current: 39.75
During the past 13 years, the highest EV-to-EBITDA of ArcticZymes Technologies ASA was 3189.91. The lowest was -738.44. And the median was 53.57.
LTS:0DRV's EV-to-EBITDA is ranked worse than 77.11% of 402
companies
in the Biotechnology industry
Industry Median: 14.41
vs LTS:0DRV: 39.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ArcticZymes Technologies ASA's PE Ratio (TTM) for today is calculated as:
ArcticZymes Technologies ASA's share price for today is kr21.00.
ArcticZymes Technologies ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.300.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRV vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, ArcticZymes Technologies ASA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ArcticZymes Technologies ASA EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ArcticZymes Technologies ASA's EV-to-EBITDA falls into.
ArcticZymes Technologies ASA's current Enterprise Value is kr827.1 Mil.
ArcticZymes Technologies ASA's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ArcticZymes Technologies ASA (LTS:0DRV) has a EV-to-EBITDA of 39.76 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ArcticZymes Technologies ASA. This is 26% below median its historical median of 53.57. According to the industry distribution chart, ArcticZymes Technologies ASA ranks #310 out of 402 companies in the Biotechnology industry, placing it in the top 77.1%.
Is ArcticZymes Technologies ASA's EV-to-EBITDA too high?
ArcticZymes Technologies ASA's current EV-to-EBITDA of 39.76 is 26% below median its 10-year median of 53.57. The Biotechnology industry median EV-to-EBITDA is 14.41. ArcticZymes Technologies ASA's value of 39.76 is 175.9% above this industry median. Based on the distribution chart, ArcticZymes Technologies ASA ranks #310 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ArcticZymes Technologies ASA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ArcticZymes Technologies ASA's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ArcticZymes Technologies ASA ranks #310 out of 402 companies for EV-to-EBITDA. This places ArcticZymes Technologies ASA in the lower half of its industry. The industry median EV-to-EBITDA is 14.41. ArcticZymes Technologies ASA's value of 39.76 is 175.9% above this benchmark. While the company's 10-year median is 53.57 vs. the industry median of 14.41, ArcticZymes Technologies ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.41, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ArcticZymes Technologies ASA's current EV-to-EBITDA of 39.76 is 175.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ArcticZymes Technologies ASA. For the Biotechnology industry, the median EV-to-EBITDA is 14.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ArcticZymes Technologies ASA's current EV-to-EBITDA is 39.76, which is 26% below median its own 10-year median of 53.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ArcticZymes Technologies ASA stock overvalued right now?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA (LTS:0DRV) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.93, compared to a current price of kr21.00 — trading 19% below its estimated fair value. The current EV-to-EBITDA is 39.76, which is 26% below median its 10-year median of 53.57 and 175.9% above the Biotechnology industry median of 14.41. ArcticZymes Technologies ASA's overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ArcticZymes Technologies ASA (LTS:0DRV), the current EV-to-EBITDA is 39.76 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?
Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued.
The current stock price of kr21.00 is trading 19% below its estimated GF Value™ of kr25.93.
GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.
Key valuation signals for LTS:0DRV:
EV-to-EBITDA: 39.76 (26% below median its 10-year median of 53.57)
GF Value™: kr25.93 vs. price of kr21.00 (19% below fair value)
Industry Position: 175.9% above the Biotechnology median (#310 of 402)
No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
74GF Score
Get the complete analysis for LTS:0DRV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRV has been successfully added to your 
